Form 10-Q

Minim, Inc. Announces Receipt of Nasdaq Listing Deficiency Notice

Retrieved on: 
Monday, November 20, 2023
Due Date, Form, Notice, Calendar, Form 10-Q, Security (finance)

The Notice has no immediate effect on the listing or trading of the Company’s securities.

Key Points: 
  • The Notice has no immediate effect on the listing or trading of the Company’s securities.
  • Pursuant to Listing Rule 5250(c)(1), the Company was required to file the Form 10-Q by November 14, 2023 (the “Due Date”).
  • Nasdaq has informed the Company that, under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice to submit a plan to regain compliance with the Rule.
  • However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.

CUEN - Cuentas Achieves Remarkable Third Quarter Results, Showcasing an Astounding 861% Revenue Surge Compared to the Previous Quarter in 2023, Alongside a Noteworthy 200% Year-over-Year Growth in Cash Position.

Retrieved on: 
Monday, November 20, 2023
Q3, Marketing, Fintech, MIAMI, WHEN, Telecommunications, Acquisition, Form 10-Q, OTC Markets Group, Gartner, Housing, Artificial intelligence, Investment, Communication, Cryptocurrency

Expenses and losses reflect a corresponding reduction due to a decrease in sales, marketing and administrative expenses.

Key Points: 
  • Expenses and losses reflect a corresponding reduction due to a decrease in sales, marketing and administrative expenses.
  • These robust financial indicators underscore the success of its expansion strategy and its commitment to delivering value across various sectors.
  • Operating Expenses were $3.512 million, compared to $9.320 million for the nine months in the previous fiscal year quarter.
  • As of September 30, 2023, cash and cash equivalents were $1.1 million.

BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, December 27, 2023
Class Action Lawsuit, Professional Services, Legal, Telephone, Risk, Class, Form, Register, News, Bank statement, Prospectus, P.C, IPO, Defendant, Form 10-Q, Security (finance)

Our investigation concerns whether the board of directors of Bioventus have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Bioventus have breached their fiduciary duties to the company.
  • Bioventus is a medical device company that focuses on developing and commercializing clinical treatments to engage and enhance the body's natural healing process.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • On this news, Bioventus's stock price fell $1.00 per share, or 33.67%, to close at $1.97 per share on November 17, 2022.

Infinera Corporation Announces Notification of Delinquency with Nasdaq

Retrieved on: 
Thursday, November 16, 2023
Listing Rules, INFN, SAN, Security (finance), Notice, Form 10-Q, Form, Late, Plan, Failure, Letter, Infinera, Cryptocurrency, Audit

SAN JOSE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) --  Infinera (NASDAQ: INFN) announced today that it received a delinquency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on November 10, 2023 (the “Notice”).

Key Points: 
  • SAN JOSE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) --  Infinera (NASDAQ: INFN) announced today that it received a delinquency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on November 10, 2023 (the “Notice”).
  • The Notice indicated that Infinera was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”), as described more fully in Infinera’s Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2023.
  • The Listing Rule requires listed companies to timely file all required periodic financial reports with the SEC.
  • Nasdaq has informed Infinera that it must submit a plan of compliance (the “Plan”) by January 9, 2024 addressing how it intends to regain compliance with Nasdaq’s listing rules.

AGBA Group Releases Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, Security (finance), Coronavirus, Public expenditure, USD, Form 10-Q, Cryptocurrency, Hong Kong

HONG KONG, Nov. 14, 2023 (GLOBE NEWSWIRE) --  NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for its third quarter ended September 30, 2023.

Key Points: 
  • HONG KONG, Nov. 14, 2023 (GLOBE NEWSWIRE) --  NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for its third quarter ended September 30, 2023.
  • Revenues for the third quarter of 2023 were approximately flat compared to revenues for the third quarter of 2022.
  • During the third quarter of 2023, the company expanded its platform by introducing new products and supporting services for its financial consultants and end-customers.
  • Mr. Wing-Fai Ng, Group President of AGBA Group Holding Limited stated, “We are optimistic that our dedicated efforts will continue to provide momentum to successfully close out 2023 and continue our upward trajectory in 2024.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PacWest Bancorp of Class Action Lawsuit and Upcoming Deadline – PACW

Retrieved on: 
Monday, November 13, 2023
Defendant, Sale, Ext, PacWest Bancorp, Pressure, Safety, Banc of California, Silicon Valley Bank, LLP, PWB, Action Replay, Pomerantz, Investment, Bank holding company, Complaint, Signature Bank, Report, First Republic Bank, Treasury, Federal, District court, FDIC, Person, Silvergate Bank, Form 10-Q, Banq, Silvergate, Court, Fed, PacWest, News, Prior, SVB, Bank, Cryptocurrency, Security (finance), Bloomberg

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PacWest Bancorp (“PacWest” or the “Company”) (NASDAQ: PACW) and certain officers.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PacWest Bancorp (“PacWest” or the “Company”) (NASDAQ: PACW) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • PacWest operates as a holding company for its wholly-owned subsidiary, Pacific Western Bank (“PWB”), a regional bank based in Los Angeles, California.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Encephalitis, Nature, HD, Eurosport 1, Patient, Research, Neuron, Dementia, Conference, Cash, ORR, Cognition, Drug discovery, Cancer, Doctor of Philosophy, Form 10-Q, Glial fibrillary acidic protein, FCMI, Prevalence, Astrocyte, GFAP, Microglia, Blood, Head and neck cancer, Three Months, Completeness, Risk, PFS, Merck, L.L.C, SEMA4D, Clinical trial, Security, Drug, Drug development, Patent, SIGNAL, Biomarker, Brain, CCR8, Plasma, Disease, Private placement, Neurodegenerative disease, Private, Neoplasm, G protein-coupled receptor, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, HNSCC

ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.

Key Points: 
  • ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.
  • The potential impact of the AD program on Vaccinex valuation and financial resources make this Vaccinex’s most important near-term catalyst.
  • On August 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.20 million shares1 of common stock for aggregate proceeds of $0.7 million.
  • Similarly, on September 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.25 million shares of common stock for aggregate proceeds of $0.6 million.

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Breast, Acute respiratory distress syndrome, Safety, Telephone, Complaint, Mortality, Patient, Fast track (FDA), Infection, FDA, Prostate cancer, Prostate Cancer Foundation, Jeanne Eagels, Aerospace, COVID-19, Standard of care, Trial of the century, Death, P.C, Form 10-Q, Fast Track, News, Cryptocurrency, Pharmaceutical industry, Tiberius Claudius Verus

Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • At the time, there was no authorized or approved treatment for hospitalized patients with severe COVID-19 infections.

Ferguson Files Form 10-Q

Retrieved on: 
Thursday, December 7, 2023
HVAC, Other Construction & Property, Manufacturing, Construction & Property, Building Systems, Other Manufacturing, Form 10-Q, SEC filing, Ferguson plc, Security (finance)

On December 6, 2023, Ferguson plc (the "Company") filed a Form 10-Q with the U.S. Securities and Exchange Commission ("SEC"). It is available on the SEC's website at sec.gov and on the SEC Filings page of the Company's website corporate.ferguson.com/investor/financial-information/sec-filings.

Key Points: 

On December 6, 2023, Ferguson plc (the "Company") filed a Form 10-Q with the U.S. Securities and Exchange Commission ("SEC"). It is available on the SEC's website at sec.gov and on the SEC Filings page of the Company's website corporate.ferguson.com/investor/financial-information/sec-filings.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)

Retrieved on: 
Thursday, November 30, 2023
Class Action Lawsuit, Professional Services, Legal, Retirement, LLP, Form 10-Q, News, Private investigator, Eagle

The law firm of Kirby McInerney LLP is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX ).

Key Points: 
  • The law firm of Kirby McInerney LLP is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX ).
  • The investigation concerns whether Eagle and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com .